Cibus, Inc.
CBUS Healthcare Biotechnology
Cibus, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.6 million, down 14.6% from fiscal 2024. In the quarter to June 2026, revenue grew 6.54%, EPS grew 52.5%, free cash flow grew 31.6% and total debt fell 62.1%, each against the same quarter a year earlier.
Follow CBUS
Cibus, Inc. (CBUS) EV/Sales
As of 16 October 2026, Cibus, Inc. (CBUS) trades at a EV/Sales of 18.9×. Over the past ten years it has ranged from −0.4× (September 2022) to 2,145× (March 2019); the current reading is higher than 46% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 19.5× | 0.40% |
| FY2024 | 19.4× | (77.77%) |
| FY2023 | 87.1× | (17.10%) |
| FY2022 | 105× | 3,176.23% |
| FY2021 | 3.2× | (42.61%) |
| FY2020 | 5.6× | (78.48%) |
| FY2019 | 26.0× | (97.47%) |
| FY2018 | 1,025× | 4.90% |
| FY2017 | 977× | 6,250.89% |
| FY2016 | 15.4× | 0.00% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 19.7× | (15.30%) |
| Mar 2026 | 23.3× | 19.76% |
| Dec 2025 | 19.5× | 62.19% |
| Sep 2025 | 12.0× | 162.86% |
| 38 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| MIST Milestone Pharmaceuticals Inc. compare | −2.4× |
| PMVP PMV Pharmaceuticals, Inc. compare | n/m |
| IMUX Immunic, Inc. compare | n/m |
| PYPD PolyPid Ltd. compare | n/m |
| BDTX Black Diamond Therapeutics, Inc. compare | n/m |
| UNCY Unicycive Therapeutics, Inc. compare | n/m |
| NRXS Neuraxis, Inc. compare | 16.0× |
| CBUS Cibus, Inc. | 18.9× |
| ATRA Atara Biotherapeutics, Inc. compare | 20.7× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)